Clinical Trial Update: Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the safety and efficacy of a JAK1 inhibitor combined with intensive immunosuppressive therapy for severe, refractory, o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• JAK1 inhibitor

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Severe Aplastic Anemia, Refractory Aplastic Anemia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING